Medina-Catalán, David
Riera, Pau
Pagès-Puigdemont, Neus http://orcid.org/0000-0003-4788-2728
Masip, Montserrat
López-Ferrer, Anna
Vilarrasa, Eva
Puig, Lluís
Article History
Received: 14 October 2021
Accepted: 10 March 2022
First Online: 5 April 2022
Declarations
:
: D. Medina-Catalán does not declare any conflict of interests.P. Riera reports grants from Ferrer and Sanofi outside the submitted work.N. Pagès-Puigdemont has perceived consultancy/speaker’s honoraria and grants/research from Abbvie, Amgen, Boehringer Ingelheim, Celgene, Janssen, MSD, Novartis, Pfizer, Roche, Sanofi and UCB.M. Masip has perceived consultancy/speaker’s honoraria and grants/research from Abbvie, Amgen, Celgene, Janssen, MSD, Novartis, Pfizer, Roche and UCB.E. Vilarrasa has perceived consultancy/speaker’s honoraria from and/or participated in clinical trials sponsored by Abbvie, Almirall, Amgen, Bayer, Boehringer Ingelheim, Celgene, Gebro, Isdin, Janssen, Leo-Pharma, Lilly, Merck-Serono, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi, and UCB. Not related to the submitted work.A. López-Ferrer reports personal fees for participation as an advisory board member, consultant and/or speaker, and grants/research support for participation in clinical trials with AbbVie, Almirall, Amgen, Celgene, Janssen, LEO Pharma, MSD, Eli Lilly, Novartis and UCB Pharma. Not related to the submitted work.L. Puig has perceived consultancy/speaker’s honoraria from and/or participated in clinical trials sponsored by Abbvie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Gebro, Janssen, JS BIOCAD, Leo-Pharma, Lilly, Merck-Serono, MSD, Mylan, Novartis, Pfizer, Regeneron, Roche, Sandoz, Samsung-Bioepis, Sanofi, and UCB.